BEVERLY, Mass., Oct. 19, 2009 (GLOBE NEWSWIRE) — Cellceutix Corporation (OTCBB:CTIX) today announced that data recently presented by the Company at the American Association for Cancer Research (AACR) along with other data developed by the Company indicate that Kevetrin is selectively targeting very specific anti-tumor pathways, such as AKT and p38 MAP kinase. The data presented at the AACR showed that Kevetrin was less cytotoxic than paclitaxel, cisplatin and 5FU while having better anti-tumor activity in two multi-drug resistant lung cancer cell lines. This indicates that Kevetrin is not acting primarily as a cytotoxic agent but may be targeting specific components of the signal transduction pathway, such as AKT and p38 MAP kinase. The Company is continuing to explore other potential targets.

Other data developed by the Company indicate that Kevetrin has potent anti-tumor activity in one cell line (MDA-MB–231) despite only partially inhibiting AKT in that cell line.

...

Kevetrin(TM) Shows Excellent Activity in Animal Models of Drug Resistant Lung Cancer With Less Cytotoxicity Than Paclitaxel

Cellceutix of Beverly, MA, to Pursue Development for Drug-Resistant Lung Cancer

BEVERLY, Mass., Oct. 13, 2009 (GLOBE NEWSWIRE) — Cellceutix Corporation (OTCBB:CTIX) today announced that it presented a poster and its Chief Scientific Officer, Dr. Krishna Menon, was one of only four individuals selected to participate in an expert panel discussion of the abstract at the American Association for Cancer Research (AACR) meeting “Frontiers in Basic Cancer Research” in Boston, MA on October 10, 2009. The Company’s poster describes in vitro and in vivo research on its lead compound, Kevetrin(TM), which is being developed for drug resistant cancers. The three day AACR meeting featured presentations on the latest advances in basic cancer research from around the world. The AACR issued a press release on October 10, 2009 which featured the abstract submitted

...

Yesterday, Schering-Plough Corp. (SGP) and Johnson & Johnson (JNJ) announced the approval of their drug Simponi (golimumab) in the European Union for the treatment of rheumatoid arthritis and other immune system disorders. The drug was approved by the U.S. Food and Drug Administration (FDA) in April 2009.   As a reminder, Schering acquired co-development rights to Simponi in the third quarter of 2005 from Johnson & Johnson’s biotech arm, Centocor Inc., which had developed and discovered the drug. Johnson & Johnson enjoys exclusive marketing rights of Simponi in the U.S., while Schering-Plough holds marketing rights outside the U.S.  excluding Japan, Indonesia and Taiwan where the drug will be co-marketed with other vendors subsequent to regulatory approvals.   Simponi, a next-generation, fully human, anti-tumor necrosis factor (TNF), received European approval as a once-a-month treatment for rheumatoid arthritis (RA), psoriatic arthritis (PA) and ankylosing spondylitis (AS), which is a ...

Oct. 6, 2009 (Business Wire) — SmallCapVoice.com, Inc. announced today that a new audio interview with Cellceutix Corporation (OTCBB: CTIX), an emerging bio-pharmaceutical company in the business of developing small-molecule therapies in areas of unmet medical needs, is now available. The interview can be heard at http://smallcapvoice.com/blog/10-5-09-audio-interview-with-cellceutix-corp-otcbb-ctix.

SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients’ financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and investor fact sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Wednesday September 30, 2009

DrStockPick.com Stock Report!

COV, PWRM, MSFT, CSRH, NKE, CVAT, ABT

**************************************************************

COV, Covidien plc

COV engages in the development, manufacture, and sale of healthcare products for use in clinical and home settings worldwide. The company operates through four segments: Medical Devices, Imaging Solutions, Pharmaceutical Products, and Medical Supplies.

COV said Wednesday it received Food and Drug Administration clearance for its new endotracheal tube, a device that helps patients breathe.

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Monday September 28, 2009

DrStockPick.com Stock Report!

XRX, PWRM, ABT, CSRH, CMCSA, CVAT, FMCN

**************************************************************

XRX, Xerox Corp.

XRX engages in the development, manufacture, marketing, servicing, and financing of document equipment, software, solutions, and services worldwide.

XRX said Monday it will buy Affiliated Computer Services Inc. for $6.4 billion in cash and stock to create a $22 billion business that combines XRX’s copiers, printers and document management services with the “business process outsourcing” of Dallas-based ACS., joining the expensive race among technology companies to broaden their offerings.

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in

...

Recently, Incyte Corporation (INCY) presented impressive data from a mid-stage trial for its pipeline candidate INCB18424 for psoriasis treatment. The phase IIb trial, carried out on 200 patients over a period of three months, compared three once-daily doses of the drug compared to the placebo. It was observed that patients treated with INCB18424 had a statistically significant improvement over the placebo in reducing total lesion score (erythema + scaling + thickness), which was also the primary endpoint of the trial. In addition, the trial met its secondary endpoint which was the Physician Global Assessment score and the Psoriasis Area and Severity Index score. Apart from psoriasis, Incyte is conducting trials of INCB18424 for several other indications which include myelofibrosis, polycythemia vera/essential thrombocythemia, rheumatoid arthritis, refractory prostate cancer and multiple myeloma. Incyte has other potential candidates targeting treatment for diabetes, breast cancer and HIV. However, the ...

Provectus Pharmaceuticals, Inc.

(Public, OTC:PVCT)

StocksHaven Investments profiles one of the most exciting up-and-coming anti-cancer companies in the industry, Provectus Pharmaceuticals (OTC:PVCT). They have one of the deepest pipelines of any small cap biotech, focusing on treatments for: Melanoma, Psoriasis, Atopic Dermatitis, Breast Cancer, and Liver Metastasis. With three drugs nearly ready to enter Phase III, including one nearly entering Phase II for Breast Cancer, one of the largest target markets worldwide and seeking “compassionate use” in Australia and USA, look for Provectus to make a splash within the next couple of months.

They are developing and testing one of the most exciting anti- cancer compounds. It has been demonstrating significant effectiveness against Melanoma in Phase 2 clinical trials and it offers promising treatment for breast, liver and other solid tumor based metastatic cancers. The compound developed by Provectus, known as PV-10, is a

...

Provectus Pharmaceuticals Inc. is quickly gaining a reputation as an up-and-coming development-stage oncology and dermatology biopharmaceutical company. Helping to enhance this reputation and its position in the marketplace, Provectus announced the addition of Mount Sinai School of Medicine as the second and final site for its expanded Phase 2 clinical trial of the company’s lead dermatology agent PH-10 for psoriasis. Jason Elmer, M.D., who served as the lead investigator for the Phase 2 clinical trial of PH-10 for atopic dermatitis of which patent enrollment was completed in June, will also serve as the principal investigator of this trial.

Commenting on the value of Dr. Elmer’s work on this project, Provectus CEO Craig Dees, Ph.D. stated, “Dr. Emer’s work with PH-10 for atopic dermatitis, his involvement in the ongoing research of the product as a dermatological therapy, and Mount Sinai School of Medicine’s outstanding reputation in dermatological research make this

...

Stock-PR OTC Stock Report August 18, 2009

Insight Management Corporation (OTCBB: ISIM) President and CEO, Jennifer Rapacki, August 18, 2009 commented on positive trends in the domestic natural gas services market. “While existing natural gas wells continue to demand maintenance, new drilling activity should create added demands for service,” Ms. Rapacki noted. “We are now seeing an increase in leasing activity and are very encouraged about how that will translate into higher revenues for service companies like ours in the remainder of this year.”

Sector 10, Inc. (OTCBB:SECI) (Frankfurt:4SR) announced that it has submitted proposals to multiple cities regarding the deployment of the Pilot PLX-3D system. The proposals were sent in response to inquiries received from the announcement of the Pilot PLX-3D deployment program in the July 21, 2009 press release. The PLX-3D deployment and the related installation of SRU’s are designed to help communities better prepare for emergencies, disasters and

...